Recent reports elucidated that HSPA5 upregulation negatively regulates ferroptosis in pancreatic cancer, while ATF4 activation upregulates HSPA5, thus the HSPA5-GPX4 pathway is one of the causes of gemcitabine resistance (Zhu S. et al., 2017). This evidence concerns the gene GPX4 and familial pancreatic carcinoma.